We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Pfenex Awards a Contract to Paragon Bioservices


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Pfenex Awards a Contract to Paragon Bioservices"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

Pfenex Inc. has announced that it has awarded Paragon Bioservices a contract for the current Good Manufacturing Practice (cGMP) manufacturing of its rPA based anthrax vaccine.

Paragon Bioservices will implement the cGMP-ready Pfēnex Expression Technology™-based production process that has been developed at Pfenex, through its vaccines division.

Funding will be provided by the Department of Health and Human Services (HHS), through the Biomedical Advanced Research and Development Authority (BARDA).

“We are pleased to award this contract to Paragon Bioservices,” stated Bertrand C. Liang, Chief Executive Officer, “This is the next step in reaching our common objective with BARDA to develop an anthrax vaccine with a product capable of achieving the goals of the Strategic National Stockpile for the U. S. Government, including cost, shelf life, and administration improvements. With Paragon Bioservices we believe we will rapidly implement the large-scale cGMP production of the rPA required for our Phase 1 clinical trial.”

Marco A. Chacón, Ph.D., CEO of Paragon stated, “My team and I are dedicated to providing manufacturing support to Pfenex, using their powerful protein expression technology. This project becomes all the more important since it will enrich the national armamentarium of vaccines against potential bio weapons.”

Advertisement